ProMIS Neurosciences to Present Preclinical Data on Alzheimer’s Disease Therapeutic Antibody PMN310 at Alzheimer’s Association International Conference
PMN310 Shows Potential for Best in Class Amyloid-Beta Oligomer Selectivity
TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 10, 2018– ProMIS Neurosciences, Inc. (TSX: PMN; OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that the Company will present preclinical data on its lead product candidate for Alzheimer’s disease (AD), PMN310, at the Alzheimer’s Association International Conference (AAIC) to be held in Chicago Illinois on July 22-26.
Advances in the understanding of Alzheimer’s disease (AD) pathogenesis suggest that progressive neurodegeneration is not caused by plaque but rather by low molecular weight (LMW) soluble toxic amyloid-beta oligomers (AβO). Binding of Aβ monomers and/or fibrils by therapeutic antibodies has been associated with suboptimal efficacy and adverse events in clinical trials.
Dr. Elliot Goldstein, ProMIS President and CEO stated: “PMN310 was selected as our lead product for development on the basis of its ability to selectively target and neutralize toxic Aβ oligomers with no significant off-target binding to Aβ monomers or plaque. In addition to aducanumab, encouraging results have been reported with a second clinical program, BAN2401, targeting toxic forms of Aβ. We believe the particular, oligomer selective profile of PMN310 supports a potential best in class profile compared to these other Aβ therapeutic antibodies currently showing promising results in clinical trials.”
The poster by Kaplan (et al.), is entitled Humanized PMN310 shows enhanced therapeutic potential by binding toxic low molecular weight Aβ oligomers while avoiding ARIA-related binding to Aβ deposits in AD patient brains. The data shows preferential binding of PMN310 to the toxic oligomer-enriched fraction from AD patient brains compared to other Aβ – directed therapeutic antibodies.
Johanne Kaplan, ProMIS Chief Development Officer, commented on the presentation: “Our results to be presented at AAIC indicate PMN310 may provide greater therapeutic potency and safety compared to other Aβ-directed antibodies due to its selective targeting of soluble toxic oligomers and the consequently reduced risk of amyloid related imaging abnormalities, or ARIA, allowing for safe administration of higher doses of antibody.”
The session and presentation details are as follows:
Poster Session P2-02 – “Therapeutics: Preclinical (nonhuman)”, Poster P2-048
Monday July 23, 9:30 AM – 4:15 PM
McCormick Place, Hall F-1
ProMIS is very pleased to contribute to this year’s AAIC, the world’s largest forum where international investigators, clinicians and care providers gather to share the latest study results, theories and discoveries that will help bring the world closer to breakthroughs in dementia science.
PMN310 is currently in late preclinical development with anticipated start of clinical trials in the second half of 2019.
BAN2401 is a humanized monoclonal antibody for AD, currently in clinical development by Esai/Biogen
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.
For further information please consult the Company’s website at: www.promisneurosciences.com
Follow us on Twitter
Like us on LinkedIn
Media inquiries for ProMIS
Tel. 858 717-2310
Investor Relations inquiries for ProMIS
Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785
Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
Media Inquiries for Selexis
Sam Brown Inc.
Company Inquiries for Selexis
Head, Corporate Communications
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release. This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.